ADARx Targets a $350 Million IPO With AbbVie Buying Alongside

SAN DIEGO, September 21, 2026. ADARx Pharmaceuticals is asking the IPO market to fund a broad siRNA pipeline at unusual scale, with a strategic investor helping define the demand picture. The company plans to sell 21.875 million shares at $15 to $17 each, a $328.1 million to $371.9 million raise before the underwriters’ option, according to its latest amended registration statement. The shares would list on the Nasdaq Global Select Market under ADRX.

The more consequential term sits beside the public book. AbbVie has agreed to buy shares at the IPO price in a concurrent private placement, enough to own approximately 4.9% of ADARx after the offering, subject to a $100 million cap. Based on the disclosed pre-offering share count and base deal size, IPOGrid calculates that purchase at roughly 5.7 million shares, or approximately $85 million to $97 million across the proposed range. The placement is conditioned on the IPO closing, although the IPO is not conditioned on the placement. For public investors, this is tangible strategic validation from an existing research partner, even if it is not the same as disclosed indications of interest in the marketed IPO itself.

The bank group also gives the transaction more shape than most development-stage biotech deals. J.P. Morgan, Morgan Stanley, TD Securities and UBS are representatives, and those firms plus LifeSci Capital are bookrunners. The underwriters have a 30-day option for another 3.281 million shares. No named cornerstone orders or public-book indications of interest are disclosed, so the AbbVie purchase remains the clearest demand signal.

A liquid company seeking substantially more capital

ADARx enters marketing with $427.3 million of cash, cash equivalents and short-term investments as of June 30. It had already raised $352.5 million from preferred stock and convertible notes and received $335 million under its AbbVie collaboration, the September 14 prospectus says. The company recorded just $2.9 million of collaboration revenue in the first half of 2026 and lost $48.4 million, versus a $33.6 million loss a year earlier. Its accumulated deficit reached $269.1 million.

That balance sheet makes this a pipeline acceleration financing rather than an immediate rescue. At the $16 midpoint, the base IPO would add $350 million gross, while the AbbVie placement would lift the combined gross capital injection to roughly $441 million by IPOGrid’s calculation. Our interpretation is that investors are being asked to capitalize several clinical paths at once, before the principal efficacy readouts arrive, in exchange for a company that should have substantial runway and less near-term financing pressure than a typical biotech debut.

The proceeds are slated for five programs plus general research and working capital. The lead uses include Phase 2 work and potential Phase 3 development for agazisiran in complement-mediated diseases, completion of the Phase 3 STOP-HAE trial and pre-commercial work for onvuzosiran, and clinical development of ADX-626 in stroke prevention. Capital would also move obesity candidate ADX-077 and neurodegeneration candidate ADX-199 toward or into Phase 1. Management has broad discretion over the allocation.

The value case turns on a concentrated 2027 calendar

Onvuzosiran is the most advanced asset. ADARx is running the 90-patient Phase 3 STOP-HAE study in hereditary angioedema and expects topline data by the end of 2027, with a potential NDA submission in 2028 if the trial succeeds. The FDA granted the program Fast Track designation in August, according to the company’s August 24 announcement. ADARx has said the study tests dosing every three or six months, which could make durability central to the commercial argument.

Agazisiran supplies the breadth. The company is enrolling Phase 2 trials in renal diseases, paroxysmal nocturnal hemoglobinuria and geographic atrophy, with initial data in IgA nephropathy, C3 glomerulopathy and PNH expected from mid-2027 through the second half. Its current pipeline page shows three clinical-stage hepatic programs and two extrahepatic programs that remain earlier in development.

The reviewer’s concern is that deal size and scientific breadth can obscure how much of the equity story still rests on unproven clinical outcomes. ADARx has no approved products, collaboration accounting is the source of its limited revenue, and the first-half loss widened as development expanded. AbbVie’s investment and the deep underwriting syndicate reduce book-building uncertainty, but they do not reduce trial risk.

ADARx therefore arrives as one of the more substantial biotech financings on the calendar: a base IPO near $350 million, a strategic buyer alongside it, and enough existing liquidity to run multiple shots on goal. The pricing test is whether investors give full credit to that financing strength before the 2027 data begin to separate pipeline breadth from clinical value.